# Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

> **NCT00106626** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 52 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin

## Key facts

- **NCT ID:** NCT00106626
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2009-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106626, "Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00106626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*